Show simple item record

dc.contributor.authorHaversath, Marcel
dc.contributor.authorCatelas, Isabelle
dc.contributor.authorLi, Xinning
dc.contributor.authorTassemeier, Tjark
dc.contributor.authorJager, Marcus
dc.date2022-08-11T08:10:07.000
dc.date.accessioned2022-08-23T16:56:25Z
dc.date.available2022-08-23T16:56:25Z
dc.date.issued2012-11-01
dc.date.submitted2013-01-09
dc.identifier.citationCan J Physiol Pharmacol. 2012 Nov;90(11):1434-45. doi: 10.1139/y2012-123. <a href="http://dx.doi.org/10.1139/y2012-123">Link to article on publisher's site</a>
dc.identifier.issn0008-4212 (Linking)
dc.identifier.doi10.1139/y2012-123
dc.identifier.pmid23181272
dc.identifier.urihttp://hdl.handle.net/20.500.14038/42924
dc.description.abstractOsteoarthritis and lesions to cartilage tissue are diseases that frequently result in impaired joint function and patient disability. The treatment of osteoarthritis, along with local bone defects and systemic skeletal diseases, remains a significant clinical challenge for orthopaedic surgeons. Several bone morphogenetic proteins (BMPs) are known to have osteoinductive effects, whereof BMP-2 and BMP-7 are already approved for clinical applications. There is growing evidence that the metabolism of bone as well as the cartilage damage associated with the above disease processes are strongly inter-related with the interactions of the inflammation-related pathways (in particular prostaglandin E(2) (PGE(2))) and osteogenesis (in particular bone morphogenetic protein-2 (BMP-2)). There is strong evidence that the pathways of prostaglandins and bone morphogenetic proteins are intertwined, and they have recently come into focus in several experimental and clinical studies. This paper focuses on PGE(2) and BMP-2 intertwining pathways in bone and cartilage metabolism, and summarizes the recent experimental and clinical data.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23181272&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1139/y2012-123
dc.subjectDinoprostone
dc.subjectBone Morphogenetic Protein 2
dc.subjectOsteoblasts
dc.subjectOsteoclasts
dc.subjectOsteogenesis
dc.subjectProstaglandins
dc.subjectOrthopedics
dc.subjectPhysiology
dc.titlePGE(2) and BMP-2 in bone and cartilage metabolism: 2 intertwining pathways
dc.typeJournal Article
dc.source.journaltitleCanadian journal of physiology and pharmacology
dc.source.volume90
dc.source.issue11
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/ortho_pp/125
dc.identifier.contextkey3569974
html.description.abstract<p>Osteoarthritis and lesions to cartilage tissue are diseases that frequently result in impaired joint function and patient disability. The treatment of osteoarthritis, along with local bone defects and systemic skeletal diseases, remains a significant clinical challenge for orthopaedic surgeons. Several bone morphogenetic proteins (BMPs) are known to have osteoinductive effects, whereof BMP-2 and BMP-7 are already approved for clinical applications. There is growing evidence that the metabolism of bone as well as the cartilage damage associated with the above disease processes are strongly inter-related with the interactions of the inflammation-related pathways (in particular prostaglandin E(2) (PGE(2))) and osteogenesis (in particular bone morphogenetic protein-2 (BMP-2)). There is strong evidence that the pathways of prostaglandins and bone morphogenetic proteins are intertwined, and they have recently come into focus in several experimental and clinical studies. This paper focuses on PGE(2) and BMP-2 intertwining pathways in bone and cartilage metabolism, and summarizes the recent experimental and clinical data.</p>
dc.identifier.submissionpathortho_pp/125
dc.contributor.departmentDepartment of Orthopedics and Physical Rehabilitation
dc.source.pages1434-45


This item appears in the following Collection(s)

Show simple item record